KEVIN WIECZENSKI: Open Payments
NPI 1811674278 · FONDA, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$740 in 34 payments from 12 companies in 2025. Trend: 2023 $66 · 2024 $563 · 2025 $740
Food & beverage: $740
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $142 |
| Novo Nordisk Inc | 5 | $116 |
| ABBVIE INC. | 5 | $112 |
| Lilly USA, LLC | 5 | $111 |
| PFIZER INC. | 2 | $58 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $45 |
| Amgen Inc. | 2 | $39 |
| SHIELD THERAPEUTICS INC | 2 | $36 |
| Dexcom, Inc. | 1 | $25 |
| GlaxoSmithKline, LLC. | 1 | $21 |
Products named: AIRSUPRA, MOUNJARO, ELIQUIS, VRAYLAR, Ozempic, Wegovy, JARDIANCE, QULIPTA.
Industry payments across NY — which companies pay providers there.
